Furthermore, the in vivo experiments further identified the antitumor effects of inhibiting LINRIS in CRC, and the analysis of LINRIS/IGF2BP2 expression in the tissues from patients indicated their unique role in the development of CRC; all of these experimental results confirmed the therapeutic potential of targeting the LINRIS-IGF2BP2-MYC axis. This evidence concerns the gene LINC00920 and colorectal carcinoma.